US Broker Ratings

Kiniksa Pharmaceuticals, Ltd. (KNSA) Stock Analysis: Exploring a 27% Potential Upside with Strong Buy Ratings

For investors seeking promising opportunities in the healthcare sector, Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) may warrant a closer look. This London-based biopharmaceutical company is making waves with its innovative therapies..

Warby Parker Inc. (WRBY) Stock Analysis: Navigating a 52.81 Forward P/E in the Healthcare Sector

For investors seeking opportunities in the healthcare sector, Warby Parker Inc. (NYSE: WRBY) presents an intriguing case. With a market capitalization of $3.26 billion, the eyewear company has carved out..

UFP Technologies, Inc. (UFPT) Stock Analysis: A 60% Upside Potential in the Healthcare Sector

UFP Technologies, Inc. (NASDAQ: UFPT) is attracting considerable attention from investors, particularly in the healthcare sector, where it has carved a niche as a key player in the medical devices..

NewAmsterdam Pharma (NAMS) Stock Analysis: Potential 63% Upside in Pioneering Biotech

NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), a pioneering force in the biotechnology sector, is capturing investor interest with its promising pipeline and significant potential upside. Headquartered in Naarden, the Netherlands,..

Scholar Rock Holding Corporation (SRRK): Investor Outlook on a Biotech Powerhouse with 58% Upside

Scholar Rock Holding Corporation (NASDAQ: SRRK) stands out as a compelling investment opportunity in the biotechnology sector, particularly for investors with a keen interest in companies poised for substantial growth..

CG Oncology (CGON) Stock Analysis: 75% Upside Potential in Biotech Sector

CG Oncology, Inc. (NASDAQ: CGON) is generating a buzz in the biotechnology sector with its impressive potential upside, making it a compelling consideration for investors seeking growth in the healthcare..

Ascentage Pharma Group (AAPG): Navigating the Biotech Terrain with an Eye on Innovation

Ascentage Pharma Group International (AAPG), a clinical-stage biotechnology company based in Suzhou, China, is carving out a niche in the healthcare sector with its focus on developing therapies for cancers,..

Acadia Healthcare Company, Inc. (ACHC) Investor Outlook: Analyzing a 35% Upside Potential with Strategic Growth

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) is a significant player in the behavioral healthcare sector, serving the United States and Puerto Rico with a diverse range of services. With a..

Perrigo Company plc (PRGO) Investor Outlook: Evaluating a Compelling 53% Upside Potential

Perrigo Company plc (NYSE: PRGO), a Dublin-based leader in the healthcare sector, has grabbed investor attention with its promising 53.38% upside potential. Specializing in over-the-counter health and wellness solutions, the..

Concentra Group Holdings Parent (CON): Investor Outlook with a Promising 23.68% Upside Potential

Concentra Group Holdings Parent, Inc. (NYSE: CON), a prominent player in the healthcare sector, offers investors an intriguing opportunity with its strong market positioning and strategic offerings in occupational health..

HUTCHMED (China) Limited (HCM) Stock Analysis: Exploring a 41.69% Potential Upside in the Healthcare Sector

HUTCHMED (China) Limited (NASDAQ: HCM) is a prominent player in the healthcare sector, specifically within the drug manufacturing industry. Headquartered in Hong Kong, the company is making significant strides in..

Arrowhead Pharmaceuticals, Inc. (ARWR) Stock Analysis: A Potential 69.87% Upside Beckons Investors

Investors with a keen eye on the biotechnology sector may find Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) a compelling opportunity, especially with the stock’s potential upside of nearly 69.87% based on..

Catalyst Pharmaceuticals, Inc. (CPRX) Investor Outlook: Biotech Stock with a 70% Upside Potential

Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a prominent player in the biotechnology industry, continues to capture the attention of individual investors with its promising growth prospects and robust performance metrics. As..

Belite Bio, Inc (BLTE) Stock Analysis: Eyeing a 38.87% Upside with Breakthrough Biotech Innovations

Belite Bio, Inc (NASDAQ: BLTE) stands out in the biotechnology sector, capturing the attention of investors with a promising portfolio focused on addressing unmet medical needs in retinal degenerative diseases...

Merus N.V. (MRUS) Stock Analysis: Unveiling a 34.51% Potential Upside in the Biotech Sector

For investors scouting the dynamic landscape of biotechnology, Merus N.V. (NASDAQ: MRUS) presents a compelling narrative. Specializing in the cutting-edge field of immuno-oncology, Merus is a clinical-stage company based in..

PROCEPT BioRobotics Corporation (PRCT) Stock Analysis: A Potential 68.55% Upside in the Medical Device Arena

Investors with an eye on the healthcare sector, particularly in medical devices, might want to take a closer look at PROCEPT BioRobotics Corporation (NASDAQ: PRCT). With a focus on innovative..

Arcellx, Inc. (ACLX) Stock Analysis: 59% Potential Upside Ignites Investor Interest in Biotech Innovator

Arcellx, Inc. (NASDAQ: ACLX), a burgeoning player in the biotechnology sector, is drawing significant attention from investors, thanks to its promising portfolio of immunotherapies targeting cancer and other incurable diseases...

Envista Holdings Corporation (NVST) Stock Analysis: Navigating Growth Potential in the Dental Sector

Envista Holdings Corporation (NYSE: NVST), a prominent player in the healthcare sector, specializes in the development and sale of dental products across the globe. With a market capitalization of $3.51..

Metsera, Inc. (MTSR) Stock Analysis: Exploring a 68% Upside Potential in Biotechnology

Metsera, Inc. (MTSR) has captured investor attention with its impressive 68.09% potential upside, making it a noteworthy player in the healthcare sector’s biotechnology industry. Based in New York, Metsera is..

Protagonist Therapeutics, Inc. (PTGX) Stock Analysis: Exploring a 24% Upside Potential in the Biotech Sector

Protagonist Therapeutics, Inc. (NASDAQ: PTGX) is capturing the attention of investors with its innovative approach in the biotechnology sector. Headquartered in Newark, California, this biopharmaceutical company is making significant strides..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds